Literature DB >> 1359600

Alpha-2-adrenoceptor control of cortisol and ACTH in normal volunteers: preliminary open trial of the effects of acute and chronic idazoxan.

P Glue1, S Wilson, G M Campling, M Knightly, M Franklin, P J Cowen, D J Nutt.   

Abstract

To examine the role of alpha 2-adrenoceptors in the control of cortisol and ACTH, hormone responses to the selective alpha 2-antagonist idazoxan were studied in 12 normal volunteers. Plasma cortisol and ACTH were measured from 0930h-1230h on three occasions: before, on the 1st day, and on the 22nd day of an open treatment trial with idazoxan 40 mg administered three times per day. Compared with pretreatment cortisol levels, acute but not chronic idazoxan treatment attenuated the normal diurnal fall in plasma cortisol. Plasma ACTH concentrations were not altered by either dose of idazoxan. The attenuation of the diurnal fall in cortisol after acute idazoxan may be mediated through increased central availability of norepinephrine, and is similar to responses after high doses of the less selective alpha 2-antagonist yohimbine. Activity of central noradrenergic neurons appears to be reduced or normalized by chronic idazoxan, indicated by restoration of the normal diurnal fall in cortisol.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1359600     DOI: 10.1016/0306-4530(92)90066-g

Source DB:  PubMed          Journal:  Psychoneuroendocrinology        ISSN: 0306-4530            Impact factor:   4.905


  2 in total

1.  Melatonin responses to clonidine and yohimbine challenges.

Authors:  S H Kennedy; W Gnam; E Ralevski; G M Brown
Journal:  J Psychiatry Neurosci       Date:  1995-07       Impact factor: 6.186

Review 2.  Therapeutic Potential of Selectively Targeting the α2C-Adrenoceptor in Cognition, Depression, and Schizophrenia-New Developments and Future Perspective.

Authors:  Madeleine Monique Uys; Mohammed Shahid; Brian Herbert Harvey
Journal:  Front Psychiatry       Date:  2017-08-14       Impact factor: 4.157

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.